INT60198

Context Info Confidence 0.48 First Reported 1993 Last Reported 2010 Negated 1 Speculated 3 Reported most in Body Documents 54 Total Number 58 Disease Relevance 11.56 Pain Relevance 10.27

cytosol (JUN) nucleoplasm (JUN) nuclear chromosome (JUN) aging (JUN) nucleus (JUN) DNA binding (JUN)

Anatomy Link Frequency macrophages 2 glial cells 1 HL-60 1 proximal 1 nucleus 1 JUN (Homo sapiens)

Pain Link Frequency Relevance Heat metalloproteinase 432 99.76 agonist 36 99.44 Enkephalin 24 99.32 Opioid 22 98.84 Neuropeptide 4 98.40 qutenza 2 98.16 withdrawal 12 97.80 cytokine 281 97.76 Cholecystokinin 11 97.60 Inflammation 476 97.48

Disease Link Frequency Relevance Heat Peripheral Arterial Disease 58 98.68 Mesothelioma 110 98.36 Apoptosis 391 97.64 INFLAMMATION 590 97.48 Asthma 136 96.88 Repression 43 95.04 Hypersensitivity 34 91.96 Leukemia 20 90.44 Acquired Immune Deficiency Syndrome Or Hiv Infection 284 89.76 Colon Cancer 17 88.28

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

DNA-binding activity of the transcription factor activator protein-1 (AP-1) was assessed using an electrophoretic mobility shift assay.

AP-1 Binding (activity) of

1) Confidence 0.48 Published 2004 Journal Anesthesiology Section Body Doc Link 15329596 Disease Relevance 0 Pain Relevance 0

When fused with the c-jun leucine zipper domain, which binds heparin and forms homodimers, the polypeptide specifically reproduced the mitogenic and morphogenic activities of basic FGF with similar potency (EC50 = 240 pM).

c-jun Binding (binds) of associated with potency

2) Confidence 0.47 Published 1999 Journal Nat. Biotechnol. Section Abstract Doc Link 10585718 Disease Relevance 0.25 Pain Relevance 0.23

DNA-binding activity of the transcription factor activator protein-1 (AP-1) was assessed using an electrophoretic mobility shift assay.

activator protein-1 Binding (activity) of

3) Confidence 0.41 Published 2004 Journal Anesthesiology Section Body Doc Link 15329596 Disease Relevance 0 Pain Relevance 0

Electric mobility shift assay served for evaluation of activator protein 1 nuclear binding in HL-60 cells.

activator protein 1 Binding (binding) of in HL-60

4) Confidence 0.37 Published 2007 Journal Eur J Anaesthesiol Section Body Doc Link 17583593 Disease Relevance 0 Pain Relevance 0

This suggests that Fos/Jun homo- or heterodimeric complexes may interact with the 5'-CTGCGTCAGCG-3' motif, present within the human CCK promoter.

Jun Binding (interact) of associated with cholecystokinin

5) Confidence 0.36 Published 1993 Journal Neuroreport Section Abstract Doc Link 8453059 Disease Relevance 0.09 Pain Relevance 0.25

The tax1 induced c-Fos protein levels and the concurrently increased association of c-Fos/c-Jun transcription factors at the AP-1 site imply a strong functional significance in the activation of proenkephalin gene expression in tax1 expressing glial cells.

c-Jun Binding (association) of in glial cells

6) Confidence 0.36 Published 1997 Journal J. Neurovirol. Section Abstract Doc Link 9147818 Disease Relevance 0 Pain Relevance 0.13

After 1 h or 96 h of treatment, Fos and Jun protein levels were altered and the DNA-binding activity of AP-1 was increased in response to both substances.

AP-1 Binding (binding) of

7) Confidence 0.36 Published 2005 Journal Neuropharmacology Section Abstract Doc Link 15814102 Disease Relevance 0.08 Pain Relevance 0.35

After 1 h or 96 h of treatment, Fos and Jun protein levels were altered and the DNA-binding activity of AP-1 was increased in response to both substances.

AP-1 Binding (activity) of

8) Confidence 0.36 Published 2005 Journal Neuropharmacology Section Abstract Doc Link 15814102 Disease Relevance 0.08 Pain Relevance 0.35

Suppression of AP-1 was associated with altered phosphorylation of p38 mitogen-activated protein kinases.

AP-1 Binding (associated) of

9) Confidence 0.35 Published 2004 Journal Anesthesiology Section Body Doc Link 15329596 Disease Relevance 0 Pain Relevance 0

DNA-binding activity of the transcription factor activator protein-1 (AP-1) was assessed using an electrophoretic mobility shift assay.

AP-1 Binding (binding) of

10) Confidence 0.35 Published 2004 Journal Anesthesiology Section Body Doc Link 15329596 Disease Relevance 0 Pain Relevance 0

These data suggest enkephalin gene expression in the adrenal gland is controlled by cell-specific binding of transcription factors from the Fos/Jun families to the enkephalin CRE-2 element.

Jun Binding (binding) of in adrenal gland associated with enkephalin

11) Confidence 0.35 Published 1996 Journal J. Neurochem. Section Abstract Doc Link 8931456 Disease Relevance 0.07 Pain Relevance 0.68

DNA-binding activity of the transcription factor activator protein-1 (AP-1) was assessed using an electrophoretic mobility shift assay.

activator protein-1 Binding (binding) of

12) Confidence 0.31 Published 2004 Journal Anesthesiology Section Body Doc Link 15329596 Disease Relevance 0 Pain Relevance 0

Removal of the AP-1 binding site from the MMP-12 promoter abolished the basal and inducible expression of MMP-12 [23]. c-Jun, which is a predominant component of the AP-1 binding complex binding to the MMP-12 promoter [23], can potentially transactivate the MMP-12 promoter up to 20-fold in macrophages [18].

AP-1 Binding (binding) of in macrophages associated with metalloproteinase

13) Confidence 0.27 Published 2005 Journal Respir Res Section Body Doc Link PMC1363355 Disease Relevance 0.08 Pain Relevance 0.72

Removal of the AP-1 binding site from the MMP-12 promoter abolished the basal and inducible expression of MMP-12 [23]. c-Jun, which is a predominant component of the AP-1 binding complex binding to the MMP-12 promoter [23], can potentially transactivate the MMP-12 promoter up to 20-fold in macrophages [18].

Jun Binding (binding) of in macrophages associated with metalloproteinase

14) Confidence 0.23 Published 2005 Journal Respir Res Section Body Doc Link PMC1363355 Disease Relevance 0.08 Pain Relevance 0.73

The interference of PPARalpha/retinoid X receptor alpha with the AP-1 transcription factor elements c-Jun/c-Fos resulted in the inhibition of AP-1 binding and down-regulation of the VDUP-1 gene expression.

AP-1 Binding (binding) of

15) Confidence 0.21 Published 2008 Journal J. Mol. Biol. Section Abstract Doc Link 18848838 Disease Relevance 0.20 Pain Relevance 0.16

Our results provide evidence for a differential effect of chemopreventive agents such as beta-lapachone, emodin, sanguinarine and capsaicin, which significantly inhibit reporter gene expression as well as TNFalpha- and TPA-induced binding of AP-1 and NF-kappaB, whereas trans-anethole and silymarin do not produce any inhibitory effect.

AP-1 Binding (binding) of associated with qutenza

16) Confidence 0.21 Published 2004 Journal Biochem. Pharmacol. Section Abstract Doc Link 15313406 Disease Relevance 0.33 Pain Relevance 0.10

1 promoter contains binding sites for both AP-1 and NF-?

AP-1 Binding (binding) of

17) Confidence 0.20 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906809 Disease Relevance 0 Pain Relevance 0

1 promoter in a promoter reporter construct, with mutation of the AP-1 and NF-?

AP-1 Binding (mutation) of

18) Confidence 0.20 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906809 Disease Relevance 0.20 Pain Relevance 0.10

1 promoter contains binding sites for both AP-1 and NF-?

AP-1 Binding (sites) of

19) Confidence 0.20 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906809 Disease Relevance 0 Pain Relevance 0

Once bound to the promoter, cFos/cJun heterodimers can recruit the SWI/SNF chromatin remodeling complex to activate transcription, whereas homodimers or heterodimers consisting of other family members lack this ability [194].

cJun Binding (bound) of

20) Confidence 0.19 Published 2009 Journal Retrovirology Section Body Doc Link PMC2805609 Disease Relevance 0.05 Pain Relevance 0

General Comments

This test has worked.